Oncology Assays

Taipei City, Taiwan

About PlexBio PlexBio Co., Ltd., founded in 2010 and headquartered in Taiwan, is a leading developer and manufacturer of multiplex in vitro diagnostic (IVD) solutions tailored for precision medicine. At the core of PlexBio s innovation is the patented πCode® MicroDisc technology, enabling simultaneous detection of dozens to hundreds of genetic mutations or biomarkers in a single reaction. This forms the basis of the IntelliPlex® platform , supporting applications in oncology, infectious diseases, and immunoassays. To streamline laboratory workflows, PlexBio developed the IntelliPrep TRIO 240 —a fully automated sample preparation system that integrates nucleic acid extraction, quantification, normalization, and PCR assay setup. Supporting up to 24 samples per run, TRIO 240 reduces hands-on time and minimizes human error, while ensuring standardized sample prep for downstream applications such as qPCR, dPCR, NGS, or PlexBio's πCode-based detection. PlexBio is committed to improving diagnostic accuracy, reducing testing costs, and enhancing patient outcomes by delivering innovative, scalable, and cost-effective molecular testing solutions. With ISO 13485, GMP, CE-IVD, and FDA-listed products, PlexBio continues to expand globally through clinical collaborations, RUO/LDT applications, and distribution partnerships.